The Prescription Access Litigation blog's resident Advice Columnist, Ask Pharmie, has been on hiatus for a while -- but now he's back! Ask Pharmie answers readers’ questions about the pharmaceutical industry, drug marketing, drug pricing, and the like.

Gooznews says ‘Well-I-Never’ to results from a survey by marketing researchers at PeopleMetrics that talked docs about sales rep interactions around atypical antipsychotics, grouping them into ‘Fully Engaged,’ ‘Engaged,’ ‘On the Fence,’ ‘Disengaged’ (all

With headlines about Sen. Chuck Grassley’s investigations into industry payments to psychiatrists rolling in as predictably as, well, payday, PostScript thought it would be good to get a little perspective from someone in the field. So we talked last week

Yesterday, Massachusetts Gov. Patrick signed the omnibus health cost containment bill, enacting some of the strongest pharmaceutical marketing restrictions in the country. (Press release here) The law requires drug and medical device companies to disclose

For an industry that regularly tops the charts on profit margins, we weren’t surprised to see the full page ad in the Boston Globe today, signed by the Biotechnology Industry Association, Massachusetts Biotechnology Council, Associated Industries of Massa

Below is a press release that we here at Prescription Access Litigation (PAL) issued today. Three members of the PAL coalition filed a formal objection to a settlement proposed in the class action lawsuit, Carpenters & Joiners Welfare Fund et. al. v. Smi

A bill, introduced today in both House and Senate, would have the federal government go head-to-head with the pharmaceutical industry’s 100-thousand-or-so sales reps. The Independent Drug Education and Outreach Act of 2008 provides grants for the creation

The Prescription Access Litigation Blog has been on summer vacation recently, sunning itself at the beach, drinking iced tea, and playing volleyball with other blogs at Blog Camp. It's now back, tanned, rested, and ready to deliver an ice-cold cup of re

Pharmalot reports that the Pharmaceutical Researchers and Manufacturers of America surveyed 501 physicians and found that only 11 percent of doctors said that info from sales reps greatly influences their prescribing decisions.   While it looks like bad n